Alunbrig、安伯瑞、布吉他滨、布加替尼、卡布宁布格替尼

Brigatinib 90 mg

Another Name
Alunbrig、安伯瑞、布吉他滨、布加替尼、卡布宁布格替尼
Indications
The treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) patients.
Reg No
02 L 1065/24
Inspection No
0416-24
dosage form:tablet
Specs:90mg
Indate:24 months
Date：2024-9-1 Views：1023
Drug Info

COMPOSITION:

Each film-coated tablet contains Brigatinib……………………………. 90 mg

INDICATION:

LuciBriga is a kinase inhibitor indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.

DOSAGE AND USE:

90 mg orally once daily for the first 7 days; then increase to 180 mg orally once daily.

May be taken with or without food.

STORAGE:

In a dry place and store at 20°C to 25°C.

MANUFACTURED AND MARKETED BY:

LUCIUS PHARMACEUTICALS(LAO) CO., LTD

No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

WARNING:

Keep medicine out of reach of Children. Do not administer LuciBriga during Pregnancy and Lactation.

Original article, if reprinted, please indicate the link to this article: https://lucius-pharmaceuticals.com/drug/brigatinib-90-mg/

Related News